Organization (Industry)
KIMBERLY-CLARK CORPORATION
ClinicalTrials.gov lists KIMBERLY-CLARK CORPORATION as lead sponsor of 16 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Kimberly-Clark, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers KIMBERLY-CLARK CORPORATION and 2 companies grouped under it: 16 lead-sponsored trials (16 its own, 0 in the grouped companies) and 12 legal-entity registrations (9 its own, 3 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| K-C AFC MANUFACTURING S DE RL DE CV | 0 | 1 |
| Kimberly-Clark Personal Care SAS | 0 | 2 |
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dermatitis, Contact | 3 |
| Dermatitis, Irritant | 3 |
| Diaper Rash | 3 |
| Common Cold | 1 |
| Hernia, Ventral | 1 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2022 | 1 |
| 2020 | 1 |
| 2018 | 2 |
| 2017 | 5 |
| 2016 | 3 |
| 2015 | 4 |
| 2014 | 1 |
| 2012 | 2 |
| 2010 | 2 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 0 of 2 on time (n=2) |
Journals published in (47)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical microbiology | 3 |
| Menopause (New York, N.Y.) | 3 |
| Pediatric dermatology | 3 |
| PloS one | 3 |
| The Journal of investigative dermatology | 3 |
Showing 5 of 47 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,279 | 3 | 2024-08-13 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 16,447,000,000 | 2,021,000,000 | 326,000,000 |
| 2024 | 16,805,000,000 | 2,545,000,000 | 328,000,000 |
| 2023 | 17,146,000,000 | 1,764,000,000 | 303,000,000 |
| 2022 | 20,175,000,000 | 1,934,000,000 | 292,000,000 |
| 2021 | 19,440,000,000 | 1,814,000,000 | 269,000,000 |
| 2020 | 19,140,000,000 | 2,352,000,000 | 276,000,000 |
| 2019 | 18,450,000,000 | 2,157,000,000 | 284,000,000 |
| 2018 | 18,486,000,000 | 1,410,000,000 | 317,000,000 |
| 2017 | 18,348,000,000 | 2,278,000,000 | 309,000,000 |
| 2016 | 18,287,000,000 | 2,166,000,000 | 326,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (26)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-12-16 | Other financing | not disclosed | Edgar offerings |
| 2025-12-04 | Other financing | not disclosed | Sec extracted |
| 2025-11-02 | Debt financing | not disclosed | Sec extracted |
| 2025-07-25 | Other financing | not disclosed | Sec extracted |
| 2025-06-05 | Other financing | not disclosed | Sec extracted |
Showing 5 of 26 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 14 |
FDA recalls (19)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Scott¿ Moisturizing Foam Hand Sanitizer, 1.2 Liters (40.5 fl oz), Distributed in the U.S. by Kimberly-Clark Global Sales, LLC, Roswell, GA 30076-2199 Distributed in Canada by Kimberly-Clark Inc., Mississauga, Ontario L5B 3Y5 UPC 0 36000 91592 1 | Class II | 2021-02-01 |
| U by Kotex¿ Sleek¿, Regular Tampons, 18 Count | Class II | 2018-12-11 |
| U by Kotex¿ Sleek¿, Regular Tampons, 34 Count | Class II | 2018-12-11 |
| U by Kotex¿ Sleek¿, Regular/Super Tampons, 34 Count Multipack | Class II | 2018-12-11 |
| U by Kotex¿ Sleek¿, Regular Tampons, 3 Count | Class II | 2018-12-11 |
Showing 5 of 19 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 2 | 2018-12-17 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| KIMBERLY-CLARK CORPORATION | NEENAH, US | FDA | |
| KIMBERLY-CLARK CORPORATION (BEECH ISLAND MILL) | BEECH ISLAND, US | FDA | |
| Kimberly-Clark Corporation | Ogden, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Sorrento Therapeutics (United States) | Co sponsors trial with | 1 |
| Kimberly-Clark (Canada) | Parent of | 1 |
| Kimberly-Clark (Canada) | Ultimate parent of | 1 |
Latest dated events (1,364)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-04 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-02 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-25 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 1,364 events.
CLIA clinical laboratory certificates (10)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| KIMBERLY CLARK CORPORATION (MAUMELLE) | Certificate of waiver | Active |
| KIMBERLY CLARK | Certificate of waiver | Active |
| KIMBERLY CLARK CORPORATION | Certificate of waiver | Active |
| KIMBERLY CLARK CORP | Certificate of waiver | Active |
| KIMBERLY CLARK CORPORATION | Certificate of waiver | Terminated |
Showing 5 of 10 certificates.
Biomarker capability evidence (7)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| PRH1; PRH2 | Trial collaborator | Named in trial exclusion criteria |
| PSAP | Trial collaborator | Named in trial exclusion criteria |
| CAT | Trial sponsor | Mentioned in trial text |
| CD4 | Trial sponsor | Mentioned in trial text |
Showing 5 of 7 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: active development programs, approved assets, fda warning letters, fda untitled letters, and biomarkers this organization publishes on.